Shattuck Labs, Inc. (STTK) announced updated interim data from the phase IB dose expansion study of lead candidate SL-172154, in combination with azacitidine, in frontline higher-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML) patients.SL-172154 is an investigational agonist redirected checkpoint fusion protein, designed to simultaneously inhibit the CD47/SIRPα checkpoint interaction and activate the CD40 costimulatory receptor to bolster an anti-tumor immune res ...